Key information

🔎 Fund Overview

Werewolf Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The Company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the objective of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to activate selectively in the tumor microenvironment. Its clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules, respectively, for the treatment of solid tumors. It is focused on advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. Its pipeline also includes JZP898 and WTX-712.